• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

ibrutinib - Articles and news items

IMBRUVICA® for CLL

Janssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients

Industry news / 3 May 2016 / Mandy Parrett, Editorial Assistant

Janssen-Cilag International NV have reported that their therapy IMBRUVICA® (ibrutinib) has received a ‘Positive Opinion’ from the CHMP recommending that its use be extended for CLL patients.

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +